Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2001 1
2002 1
2016 1
2017 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer.
Madan RA, Karzai F, Donahue RN, Al-Harthy M, Bilusic M, Rosner II, Singh H, Arlen PM, Theoret MR, Marté JL, Cordes L, Couvillon A, Hankin A, Williams M, Owens H, Lochrin SE, Chau CH, Steinberg S, Figg WD, Dahut W, Schlom J, Gulley JL. Madan RA, et al. J Immunother Cancer. 2021 Mar;9(3):e001556. doi: 10.1136/jitc-2020-001556. J Immunother Cancer. 2021. PMID: 33664086 Free PMC article. Clinical Trial.
RESULTS: Thirty-eight patients were randomized with a median PSA=4.38 ng/dL and PSA doubling time=4.1 months. No difference was observed between the two groups for PSA growth kinetics, but PSA responses to enzalutamide were noteworthy regardless of PROSTVAC. ...The most co …
RESULTS: Thirty-eight patients were randomized with a median PSA=4.38 ng/dL and PSA doubling time=4.1 months. No difference was observed …
A double-blind, placebo-controlled, randomized clinical trial of recombinant human chorionic gonadotropin on muscle strength and physical function and activity in older men with partial age-related androgen deficiency.
Liu PY, Wishart SM, Handelsman DJ. Liu PY, et al. J Clin Endocrinol Metab. 2002 Jul;87(7):3125-35. doi: 10.1210/jcem.87.7.8630. J Clin Endocrinol Metab. 2002. PMID: 12107212 Clinical Trial.
There were no significant changes in hemoglobin, osteocalcin, or prostate-specific antigen, and the International Prostate Symptom Score did not change. Three men developed nipple tenderness that did not progress to gynecomastia. ...
There were no significant changes in hemoglobin, osteocalcin, or prostate-specific antigen, and the International Prostate Symptom Score …
Effects of a phytotherapeutic agent, PC-SPES, on prostate cancer: a preliminary investigation on human cell lines and patients.
de la Taille A, Hayek OR, Buttyan R, Bagiella E, Burchardt M, Katz AE. de la Taille A, et al. BJU Int. 1999 Nov;84(7):845-50. doi: 10.1046/j.1464-410x.1999.00285.x. BJU Int. 1999. PMID: 10532984
In the prospective clinical trial of 33 patients, with a mean (range) follow-up of 6.8 (2-24) months after initiating PC-SPES therapy, serum PSA levels were lower in 87% at 2 months and in 78% at 6 months (n=18, P=0.026). The side-effects in these patients were nipple t …
In the prospective clinical trial of 33 patients, with a mean (range) follow-up of 6.8 (2-24) months after initiating PC-SPES therapy, serum …
Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer.
Oh WK, George DJ, Hackmann K, Manola J, Kantoff PW. Oh WK, et al. Urology. 2001 Jan;57(1):122-6. doi: 10.1016/s0090-4295(00)00986-9. Urology. 2001. PMID: 11164156
METHODS: A retrospective analysis was performed of patients with prostate cancer progression despite androgen ablation therapy who were treated with PC-SPES (3 capsules twice daily). We explored potential predictors of response. RESULTS: Twenty-three patients with androgen …
METHODS: A retrospective analysis was performed of patients with prostate cancer progression despite androgen ablation therapy who were trea …
CLOMIPHENE CITRATE IN THE TREATMENT OF IDIOPATHIC OR FUNCTIONAL HYPOGONADOTROPIC HYPOGONADISM IN MEN: A CASE SERIES AND REVIEW OF THE LITERATURE.
Liel Y. Liel Y. Endocr Pract. 2017 Mar;23(3):279-287. doi: 10.4158/EP161543.OR. Epub 2016 Nov 16. Endocr Pract. 2017. PMID: 27849376
Mean basal follicle-stimulating hormone (FSH) increased from 4.2 3.6 to 8.6 6.2 nmol/L (P = .007). Testosterone and LH responses were invariably observed, including 2 patients with history of nonpituitary cranial pathologies, 2 with somewhat elevated FSH, and 1 with an eat …
Mean basal follicle-stimulating hormone (FSH) increased from 4.2 3.6 to 8.6 6.2 nmol/L (P = .007). Testosterone and LH responses were invari …